Compare MEOH & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MEOH | APLS |
|---|---|---|
| Founded | 1968 | 2009 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.7B |
| IPO Year | N/A | 2017 |
| Metric | MEOH | APLS |
|---|---|---|
| Price | $48.67 | $22.01 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 20 |
| Target Price | ★ $48.11 | $33.21 |
| AVG Volume (30 Days) | 512.4K | ★ 2.7M |
| Earning Date | 03-05-2026 | 02-27-2026 |
| Dividend Yield | ★ 1.54% | N/A |
| EPS Growth | ★ 40.35 | N/A |
| EPS | ★ 2.98 | 0.36 |
| Revenue | ★ $3,569,374,000.00 | $1,016,397,000.00 |
| Revenue This Year | $1.99 | $28.88 |
| Revenue Next Year | $12.55 | N/A |
| P/E Ratio | ★ $16.11 | $61.43 |
| Revenue Growth | N/A | ★ 42.11 |
| 52 Week Low | $25.46 | $16.10 |
| 52 Week High | $54.49 | $31.17 |
| Indicator | MEOH | APLS |
|---|---|---|
| Relative Strength Index (RSI) | 74.31 | 45.25 |
| Support Level | $44.78 | $19.26 |
| Resistance Level | $49.36 | $22.24 |
| Average True Range (ATR) | 1.57 | 1.50 |
| MACD | 0.17 | -0.34 |
| Stochastic Oscillator | 90.80 | 33.50 |
Methanex Corp manufactures and sells methanol. Its customers use methanol as a feedstock to produce end-products including adhesives, foams, solvents, and windshield washer fluids. The firm also sells its products to the oil refining industry, where the methanol is blended with gasoline to produce a high-octane fuel or blended as a component of biodiesel. It distributes its products through an extensive supply chain that includes the operation of port terminals, tankers, barges, rail cars, trucks, and pipelines. The company generates the majority of its revenue from Europe.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.